Type II Diabetes Clinical Trial
Official title:
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150 in Healthy Adults
Verified date | March 2024 |
Source | Chong Kun Dang Pharmaceutical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
Status | Completed |
Enrollment | 24 |
Est. completion date | September 5, 2023 |
Est. primary completion date | August 31, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Healthy adult aged between 19 to 55 at screening 2. Weight = 50kg(man) or 50kg(woman) 3. Body mass index (BMI) of 18.5 to 27.0kg/m2 4. If female, one of following conditions. Menopause (no menstruation more than 2 years) or surgically sterilized. 5. Those who agree to contraception from the first IP dosing day till 28 days after the last dosing day and decide not to provide sperm during the participation of clinical trial 6. Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial Exclusion Criteria: 1. Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Haemato-oncology disorder, Cardiovascular disorder or Psychical disorder. 2. Those who are vulnerable to dehydration due to lack of ability in oral intake or have dehydration. 3. Those who had medical examination requiring radioactive iodine contrast material injected through IV 48 hours prior to first IP administration. 4. Those who have significant disease or medical history of urinary infection. 5. Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 6. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption. 7. Those who have hypersensitivity to the main constituents or components of the investigational drug such as empagliflozin, metformin. 8. Those who have tested inappropriate in screening test 28 days prior to IP administration. - AST, ALT > 1.5 times higher than upper normal level - eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) < 60 mL/min/1.73m2 - "Positive" or "Reactive" test result of Hepatitis B & C, HIV, RPR - Under 5 min resting condition, systolic blood pressure >150 mmHg or or <90 mmHg, diastolic blood pressure >100 mmHg or <50 mmHg. 9. Those who has a drug abuse history within one year or positive reaction on urine drug screening test. 10. Woman who are pregnant or breastfeeding 11. Those who exceed an alcohol, caffeine and cigarette consumption (caffeine> 5 cups/day, alcohol> 210g/week, smoking> 10 cigarettes/day) and not able to stop on smoking, caffeine and alcohol 12. Those who have used following drugs that can interfere with the study or have impact on safety of the subject. - ETC, herbal medicinal preparations within 14 days before the first dosing date - OTC, vitamins, health supplement within 7 days before the first dosing date - Depot injection or implantation within 30 days before the first dosing date 13. Those who received investigational products or participated in bioequivalence test within 180 days before the first administration of clinical trial drugs 14. Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days 15. Those who have received blood transfusion in 30 days 16. Those who are deemed insufficient to participate in clinical study by investigators |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Severance Hospital | Seoul | Seodaemun-gu |
Lead Sponsor | Collaborator |
---|---|
Chong Kun Dang Pharmaceutical |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1. AUCt of CKD-378: Area under the concentration-time curve time zero to time | Pre-dose(0 hour) to 48 hours | ||
Primary | 2. Cmax of CKD-378: Maximum plasma concentration of the drug | Pre-dose(0 hour) to 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02127762 -
The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy
|
N/A | |
Withdrawn |
NCT04569214 -
The Efficacy and Safety of PAZ320 on PPG and Insulin Blood Levels in Type II Diabetic Patients
|
Phase 2 | |
Completed |
NCT01698528 -
Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration
|
N/A | |
Completed |
NCT00985114 -
Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity
|
N/A | |
Active, not recruiting |
NCT05120219 -
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04893135 -
Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the "Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes
|
N/A | |
Not yet recruiting |
NCT05108350 -
A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02586129 -
Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes
|
Phase 3 | |
Completed |
NCT02914743 -
Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes
|
N/A | |
Completed |
NCT04540016 -
Mass Balance and Biotransformation of [14C]HSK7653 in Human
|
Phase 1 | |
Completed |
NCT02429258 -
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
|
Phase 4 | |
Completed |
NCT01055223 -
Fracture Risk With Thiazolidinediones
|
N/A | |
Terminated |
NCT02365233 -
Fatty Liver Study in Patients With Type II Diabetes
|
Phase 4 | |
Completed |
NCT05878587 -
Burger Allen Exercises in Knee OA With Type II Diabetes
|
N/A | |
Completed |
NCT04768673 -
A Study to Investigate the PK and Safety of CKD-393
|
Phase 1 | |
Not yet recruiting |
NCT05028140 -
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
|
Phase 3 | |
Terminated |
NCT01804777 -
Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes
|
Early Phase 1 | |
Completed |
NCT01619332 -
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06387433 -
Effectiveness of an mHealth Mobile App
|
N/A | |
Not yet recruiting |
NCT01591525 -
Diabetes Mellitus Community Based Screening in Minority Populations
|
N/A |